関連レポート

出版元：Transparency Market Research  出版元について

発行年：2024年7月

定価：Single User License $5795 Multi User License $8795 Corporate User License $11795

ご請求は円換算（お見積り日TTSレート）となります。

ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。

納品形態：PDF by Email

当調査レポートは英文 142ページになります。

商品コード：TMR326

当レポートは発行年月に関わらず、受注の都度、最新情報にアップデートしてお届けいたします。ご希望情報の追加等もご相談可能です。

レポート紹介

糖尿病・非インスリン療法の世界市場規模は2023年で318億ドル、2034年に586億ドル、市場の平均年成長率は5.8%に到達する見込みです。

当レポートでは、糖尿病・非インスリン療法の市場予測-2034年、各種セグメント別市場分析(薬剤クラス別、投与経路別、国地域別、等)、市場ダイナミクス、パイプライン分析、主要企業プロフィールなどの情報を盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】
■糖尿病・非インスリン療法の世界市場予測2020-2034年
・市場規模(US$)

■薬剤クラス別、市場-2034年
ビグアナイド薬
スルホニル尿素剤
チアゾリジン系薬剤
α-グルコシダーゼ阻害薬
DPP-4阻害薬
GLP-1アナログ
ナトリウム・グルコース共輸送体2（SGLT2）阻害剤
※(市場規模US$)

■投与経路別、市場-2034年
経口
筋肉内
※(市場規模US$)

■エンドユーザー別、市場-2034年
病院薬局
小売薬局
オンライン薬局
※(市場規模US$)

■主要国地域別市場-2034年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・オーストラリア/ニュージーランド
・その他アジア太平洋
南米
・ブラジル、メキシコ
・その他南米
中東アフリカ
・GCC諸国、南アフリカ
・その他中東アフリカ
※地域別に各種セグメント別の細分化データ掲載、詳細は目次参照

■市場分析
市場ダイナミクス（ドライバー、障壁、機会）
パイプライン分析
主要合併/買収
競合状況

■糖尿病・非インスリン療法の主要企業プロフィール動向
GSK plc
Eli Lilly and Company
住友ファーマ株式会社
Intarcia Therapeutics
Servier Laboratories
Pfizer Inc.
Merck & Co., Inc.
Dong-A Pharmaceutical Co., Ltd.
Luye Pharma Group
Eurofarma Laboratories SA
（全142頁）

Table of Contents (英文詳細目次）

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Non-insulin Therapies for Diabetes Market

4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Non-insulin Therapies for Diabetes Market Analysis and Forecast, 2020-2034

5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Non-insulin Therapies for Diabetes Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2020-2034
6.3.1. Biguanides
6.3.2. Sulfonylureas
6.3.3. Thiazolidinediones
6.3.4. Alpha-Glucosidase Inhibitors
6.3.5. DPP-4 Inhibitors
6.3.6. GLP-1 Analogs
6.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
6.4. Market Attractiveness Analysis, by Drug Class

7. Global Non-insulin Therapies for Diabetes Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2020-2034
7.3.1. Oral
7.3.2. Intramuscular
7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Non-insulin Therapies for Diabetes Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2020-2034
8.3.1. Hospital Pharmacy
8.3.2. Retail Pharmacy
8.3.3. Online Pharmacy
8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Non-insulin Therapies for Diabetes Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region

10. North America Non-insulin Therapies for Diabetes Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2020-2034
10.3.1. Biguanides
10.3.2. Sulfonylureas
10.3.3. Thiazolidinediones
10.3.4. Alpha-Glucosidase Inhibitors
10.3.5. DPP-4 Inhibitors
10.3.6. GLP-1 Analogs
10.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
10.4. Market Value Forecast, by Route of Administration, 2020-2034
10.4.1. Oral
10.4.2. Intramuscular
10.5. Market Value Forecast, by Distribution Channel, 2020-2034
10.5.1. Hospital Pharmacy
10.5.2. Retail Pharmacy
10.5.3. Online Pharmacy
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Class
10.7.2. By Route of Administration
10.7.3. By Distribution Channel
10.7.4. By Country

11. Europe Non-insulin Therapies for Diabetes Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2020-2034
11.3.1. Biguanides
11.3.2. Sulfonylureas
11.3.3. Thiazolidinediones
11.3.4. Alpha-Glucosidase Inhibitors
11.3.5. DPP-4 Inhibitors
11.3.6. GLP-1 Analogs
11.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
11.4. Market Value Forecast, by Route of Administration, 2020-2034
11.4.1. Oral
11.4.2. Intramuscular
11.5. Market Value Forecast, by Distribution Channel, 2020-2034
11.5.1. Hospital Pharmacy
11.5.2. Retail Pharmacy
11.5.3. Online Pharmacy
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Route of Administration
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region

12. Asia Pacific Non-insulin Therapies for Diabetes Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2020-2034
12.3.1. Biguanides
12.3.2. Sulfonylureas
12.3.3. Thiazolidinediones
12.3.4. Alpha-Glucosidase Inhibitors
12.3.5. DPP-4 Inhibitors
12.3.6. GLP-1 Analogs
12.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
12.4. Market Value Forecast, by Route of Administration, 2020-2034
12.4.1. Oral
12.4.2. Intramuscular
12.5. Market Value Forecast, by Distribution Channel, 2020-2034
12.5.1. Hospital Pharmacy
12.5.2. Retail Pharmacy
12.5.3. Online Pharmacy
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Drug Class
12.7.2. By Route of Administration
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region

13. Latin America Non-insulin Therapies for Diabetes Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2020-2034
13.3.1. Biguanides
13.3.2. Sulfonylureas
13.3.3. Thiazolidinediones
13.3.4. Alpha-Glucosidase Inhibitors
13.3.5. DPP-4 Inhibitors
13.3.6. GLP-1 Analogs
13.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
13.4. Market Value Forecast, by Route of Administration, 2020-2034
13.4.1. Oral
13.4.2. Intramuscular
13.5. Market Value Forecast, by Distribution Channel, 2020-2034
13.5.1. Hospital Pharmacy
13.5.2. Retail Pharmacy
13.5.3. Online Pharmacy
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Drug Class
13.7.2. By Route of Administration
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region

14. Middle East & Africa Non-insulin Therapies for Diabetes Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Class, 2020-2034
14.3.1. Biguanides
14.3.2. Sulfonylureas
14.3.3. Thiazolidinediones
14.3.4. Alpha-Glucosidase Inhibitors
14.3.5. DPP-4 Inhibitors
14.3.6. GLP-1 Analogs
14.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
14.4. Market Value Forecast, by Route of Administration, 2020-2034
14.4.1. Oral
14.4.2. Intramuscular
14.5. Market Value Forecast, by Distribution Channel, 2020-2034
14.5.1. Hospital Pharmacy
14.5.2. Retail Pharmacy
14.5.3. Online Pharmacy
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Drug Class
14.7.2. By Route of Administration
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region

15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. GSK plc
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Eli Lilly and Company
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Sumitomo Pharma
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Intarcia Therapeutics
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Servier Laboratories
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Pfizer Inc.
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Merck & Co., Inc.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Dong-A Pharmaceutical Co., Ltd.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Luye Pharma Group
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Eurofarma Laboratories SA
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview

List of Tables

Table 01: Global Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034

Table 02: Global Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034

Table 03: Global Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

Table 04: Global Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Region, 2020-2034

Table 05: North America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Country, 2020-2034

Table 06: North America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034

Table 07: North America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034

Table 08: North America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

Table 09: Europe Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

Table 10: Europe Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034

Table 11: Europe Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034

Table 12: Europe Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

Table 13: Asia Pacific Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

Table 14: Asia Pacific Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034

Table 15: Asia Pacific Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034

Table 16: Asia Pacific Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

Table 17: Latin America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

Table 18: Latin America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034

Table 19: Latin America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034

Table 20: Latin America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

Table 21: Middle East & Africa Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

Table 22: Middle East & Africa Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034

Table 23: Middle East & Africa Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034

Table 24: Middle East & Africa Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

List of Figures

Figure 01: Global Non-insulin Therapies for Diabetes Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034

Figure 02: Global Non-insulin Therapies for Diabetes Market Revenue (US$ Bn), by Drug Class, 2023

Figure 03: Global Non-insulin Therapies for Diabetes Market Value Share, by Drug Class, 2023

Figure 04: Global Non-insulin Therapies for Diabetes Market Revenue (US$ Bn), by Route of Administration, 2023

Figure 05: Global Non-insulin Therapies for Diabetes Market Value Share, by Route of Administration, 2023

Figure 06: Global Non-insulin Therapies for Diabetes Market Revenue (US$ Bn), by Distribution Channel, 2023

Figure 07: Global Non-insulin Therapies for Diabetes Market Value Share, by Distribution Channel, 2023

Figure 08: Global Non-insulin Therapies for Diabetes Market Value Share, by Region, 2023

Figure 09: Global Non-insulin Therapies for Diabetes Market Value (US$ Bn) Forecast, 2020-2034

Figure 10: Global Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 11: Global Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034

Figure 12: Global Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034

Figure 13: Global Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034

Figure 14: Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 15: Global Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034

Figure 16: Global Non-insulin Therapies for Diabetes Market Value Share Analysis, by Region, 2023 and 2034

Figure 17: Global Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034

Figure 18: North America Non-insulin Therapies for Diabetes Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 19: North America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Country, 2024-2034

Figure 20: North America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Country, 2023 and 2034

Figure 21: North America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 22: North America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034

Figure 23: North America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 24: North America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034

Figure 25: North America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034

Figure 26:North America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034

Figure 27: Europe Non-insulin Therapies for Diabetes Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 28: Europe Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 29: Europe Non-insulin Therapies for Diabetes Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 30: Europe Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 31: Europe Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034

Figure 32: Europe Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 33: Europe Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034

Figure 34: Europe Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034

Figure 35: Europe Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034

Figure 36: Asia Pacific Non-insulin Therapies for Diabetes Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 37: Asia Pacific Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 38: Asia Pacific Non-insulin Therapies for Diabetes Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 39: Asia Pacific Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 40: Asia Pacific Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034

Figure 41: Asia Pacific Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 42: Asia Pacific Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034

Figure 43: Asia Pacific Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034

Figure 44: Asia Pacific Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034

Figure 45: Latin America Non-insulin Therapies for Diabetes Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 46: Latin America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 47: Latin America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 48: Latin America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 49: Latin America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034

Figure 50: Latin America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 51: Latin America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034

Figure 52: Latin America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034

Figure 53: Latin America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034

Figure 54: Middle East & Africa Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 55: Middle East & Africa Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 56: Middle East & Africa Non-insulin Therapies for Diabetes Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 57: Middle East & Africa Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 58: Middle East & Africa Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034

Figure 59: Middle East & Africa Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 60: Middle East & Africa Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034

Figure 61: Middle East & Africa Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034

Figure 62: Middle East & Africa Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034

△ 一番上に戻る